<code id='583BE99315'></code><style id='583BE99315'></style>
    • <acronym id='583BE99315'></acronym>
      <center id='583BE99315'><center id='583BE99315'><tfoot id='583BE99315'></tfoot></center><abbr id='583BE99315'><dir id='583BE99315'><tfoot id='583BE99315'></tfoot><noframes id='583BE99315'>

    • <optgroup id='583BE99315'><strike id='583BE99315'><sup id='583BE99315'></sup></strike><code id='583BE99315'></code></optgroup>
        1. <b id='583BE99315'><label id='583BE99315'><select id='583BE99315'><dt id='583BE99315'><span id='583BE99315'></span></dt></select></label></b><u id='583BE99315'></u>
          <i id='583BE99315'><strike id='583BE99315'><tt id='583BE99315'><pre id='583BE99315'></pre></tt></strike></i>

          Home / fashion / explore

          explore


          explore

          author:knowledge    Page View:5
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In